REXULTI (generic brexpiprazole) is a prescription psychiatric drug from Otsuka Pharmaceutical Company and Lundbeck pharmaceutical company. Although it failed Phase II clinical trials for attention-deficit hyperactivity disorder (ADHD), it was approved by the U.S. Food and Drug Administration (FDA) in 2015 as an atypical antipsychotic and prescribed for the fake “disease” schizophrenia.
Then in 2018 the FDA approved it to treat symptoms of depression when antidepressants alone do not relieve symptoms.
The cost for Rexulti oral tablet 0.25 mg is around $1,166 for a supply of 30 tablets. It has similarities to Abilify, and apparently it was developed to replace Abilify when that drug’s patent expired in 2014.
Brexpiprazole affects the levels of the neurotransmitters dopamine and serotonin in the brain. It is thought to reduce dopamine output when dopamine concentrations are high and increase dopamine output when dopamine concentrations are low. It also activates serotonin receptors to increase serotonin levels in a manner thought to reduce hallucinogenic effects, which is a problem with all drugs that mess with serotonin in the brain.
The metabolism of the drug — that is, the mechanism which eventually eliminates it from the body — is mediated by Cytochrome P450 enzymes; people who are known poor metabolizers, i.e. those with a genetic lack of these enzymes, should be instructed to take half the usual dose, although this is rarely done, since the patient must first be tested for this genetic condition. It is estimated that 10% of Caucasians and 7% of African Americans are Cytochrome P450 deficient. The consequences for someone with this deficiency who takes this drug are an increased risk for the accumulation of the non-metabolized drug in the body and the resultant increase in adverse side effects such as depression, violence and suicide.
Drugs like Rexulti can raise the risk of death in the elderly, and it is not approved for the treatment of patients with dementia-related psychosis. This drug may also increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. It is not approved for the treatment of people younger than 18 years of age.
Rexulti may cause other serious side effects, including: compulsive, uncontrollable behaviors such as gambling, shopping, binge eating and sex (the same as with Abilify); stroke in elderly people; Neuroleptic Malignant Syndrome; high fever; stiff muscles; confusion; sweating; changes in pulse, heart rate, or blood pressure; high blood sugar (hyperglycemia); weight gain; seizures; difficulty swallowing; uncontrolled body movements known as tardive dyskinesia. Tardive dyskinesia may not go away, even after one stops taking the drug, and tardive dyskinesia may also start some time after one stops taking the drug.
The real problem is that psychiatrists fraudulently diagnose life’s problems as an “illness”, and stigmatize unwanted behavior as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful. All psychiatric treatments, not just psychiatric drugs, are dangerous. Find Out! Fight Back!
